{"nctId":"NCT00628862","briefTitle":"Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU","startDateStruct":{"date":"2007-12"},"conditions":["Chronic Obstructive Pulmonary Disease"],"count":613,"armGroups":[{"label":"F 4.5 bid","type":"EXPERIMENTAL","interventionNames":["Drug: Formoterol Turbuhaler® 4.5mg"]},{"label":"F 9.0 bid","type":"EXPERIMENTAL","interventionNames":["Drug: Formoterol Turbuhaler® 9 mg"]},{"label":"PBO","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Turbuhaler® placebo"]}],"interventions":[{"name":"Formoterol Turbuhaler® 4.5mg","otherNames":["Oxis"]},{"name":"Formoterol Turbuhaler® 9 mg","otherNames":["Oxis"]},{"name":"Turbuhaler® placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males or females aged above 40 with a clinical diagnosis of COPD and current COPD symptoms\n* Current or previous smoker with a smoking history of 10 or more pack years\n* Lung function parameters: FEV1/FVC \\< 70%, post-bronchodilator and post-bronchodilator FEV1 \\< 80% of predicted normal value\n\nExclusion Criteria:\n\n* History and/or current clinical diagnosis of asthma or atopic diseases such as allergic rhinitis\n* Use of inhaled glucocorticosteroids within 4 weeks prior to Visit 2\n* Any relevant cardiovascular disorder as judged by the investigator or any current respiratory tract disorder other than COPD.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Forced Expiratory Volume in 1 Second (FEV1; L) 60 Minutes Post-dose","description":"FEV1 (expressed as litres \\[L\\]) is a spirometric measure of lung function. FEV1 was measured 60 minutes after administration of study drug. The results are expressed as a percentage in relation to the baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"112.9","spread":null},{"groupId":"OG001","value":"113.36","spread":null},{"groupId":"OG002","value":"101.28","spread":null}]}]}]},{"type":"SECONDARY","title":"Forced Vital Capacity (FVC) 60 Minutes Post-dose","description":"Forced Vital Capacity (FVC) is a spirometric measure of lung function. FVC was measured 60 minutes after administration of study drug. The results are expressed as a percentage in relation to the baseline value","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109.73","spread":null},{"groupId":"OG001","value":"109.92","spread":null},{"groupId":"OG002","value":"102.11","spread":null}]}]}]},{"type":"SECONDARY","title":"FEV1 Pre-dose","description":"Lung function (FEV1) was measured before administrations of the study drug (pre-dose). The results are expressed as a percentage of mean FEV1 over visists 4-6 in relation to the baseline (visit 3) value","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"104.54","spread":null},{"groupId":"OG001","value":"104.65","spread":null},{"groupId":"OG002","value":"99.77","spread":null}]}]}]},{"type":"SECONDARY","title":"FVC Pre-dose","description":"Lung function (FVC) was measured before administrations of the study drug (pre-dose). The results are expressed as a percentage of mean FEV1 over visists 4-6 in relation to the baseline (visit 3) value","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"103.62","spread":null},{"groupId":"OG001","value":"103.36","spread":null},{"groupId":"OG002","value":"100.73","spread":null}]}]}]},{"type":"SECONDARY","title":"FEV1 5 Minutes Post-dose","description":"Lung function (FEV1) was measured 5 minutes after the first dose of study drug. The results are expressed as a percentage in relation to the baseline value","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110.16","spread":null},{"groupId":"OG001","value":"110.24","spread":null},{"groupId":"OG002","value":"101.25","spread":null}]}]}]},{"type":"SECONDARY","title":"FVC 5 Minutes Post-dose","description":"Lung function (FVC) was measured 5 minutes after the first dose of study drug, The results are expressed as a percentage in relation to the baseline value","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108.50","spread":null},{"groupId":"OG001","value":"108.88","spread":null},{"groupId":"OG002","value":"101.59","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Peak Expiratory Flow (PEF), Morning","description":"Patients were asked to measure and record lung function (peak expiratory flow \\[PEF\\] measured in the morning). Average values over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.27","spread":"27.90"},{"groupId":"OG001","value":"18.34","spread":"26.19"},{"groupId":"OG002","value":"3.60","spread":"27.08"}]}]}]},{"type":"SECONDARY","title":"Change in Peak Expiratory Flow (PEF), Evening","description":"Patients were asked to measure and record lung function (peak expiratory flow \\[PEF\\] measured in the evening). Average values over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.15","spread":"27.52"},{"groupId":"OG001","value":"15.76","spread":"25.22"},{"groupId":"OG002","value":"2.36","spread":"26.43"}]}]}]},{"type":"SECONDARY","title":"Change in Night-time Awakenings Due to Symptoms","description":"Patients were asked to record the night-time awakenings due to symptoms (scored from 0-4 with 4 being the most severe). Period averages over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1318","spread":"0.4791"},{"groupId":"OG001","value":"-0.1748","spread":"0.5517"},{"groupId":"OG002","value":"-0.0466","spread":"0.4900"}]}]}]},{"type":"SECONDARY","title":"Breathlessness","description":"Patients were asked to record breathlessness (scored from 0-4 with 4 being the most severe). Period averages over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4068","spread":"0.6193"},{"groupId":"OG001","value":"-0.4531","spread":"0.5511"},{"groupId":"OG002","value":"-0.2626","spread":"0.5899"}]}]}]},{"type":"SECONDARY","title":"Cough","description":"Patients were asked to record cough (scored from 0-4 with 4 being the most severe). Period averages over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3250","spread":"0.6424"},{"groupId":"OG001","value":"-0.4088","spread":"0.6374"},{"groupId":"OG002","value":"-0.2016","spread":"0.6233"}]}]}]},{"type":"SECONDARY","title":"Use of Reliever Medication","description":"Patients were asked to record reliever medication use. Period averages over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.60","spread":"1.47"},{"groupId":"OG001","value":"-0.97","spread":"1.88"},{"groupId":"OG002","value":"-0.23","spread":"1.25"}]}]}]},{"type":"SECONDARY","title":"St George's Respiratory Questionnaire (SGRQ)","description":"Patients were asked to complete the St George's Respiratory Questionnaire (SGRQ). Subscale symptom score ranges from 0 to 100% and measures the effect of respiratory symptoms, frequency, and severity on quality of life. A score of 0 indicates the best possible status. Results are expressed as the change from baseline score with a decrease in score indicating improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.46","spread":"12.12"},{"groupId":"OG001","value":"-6.38","spread":"10.77"},{"groupId":"OG002","value":"-2.02","spread":"12.98"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":206},"commonTop":["Nasopharyngitis","Chronic Obstructive Pulmonary Disease"]}}}